SCHEMBL4826010

SCHEMBL4826010

CCCCC(CCCC)(c1ccc(NC(=O)/C=C/c2cnn(C)c2-c2ccc(F)cc2)cc1)P(=O)(O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.41
MMP1 P03956 4/20 0.37
MMP2 P08253 4/20 0.37
MMP9 P14780 4/20 0.37
EGFR P00533 1/20 0.37
CCNC P24863 3/20 0.36
CDK8 P49336 3/20 0.36
CDK19 Q9BWU1 1/20 0.36
MCHR1 Q99705 3/20 0.36
LMNA P02545 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SNCA P37840 1/20 0.36
GRM5 P41594 1/20 0.35
PTK2 Q05397 1/20 0.35
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826020 1.00 MAOB (0.41) MAOBMMP1MMP2MMP9EGFR
SCHEMBL4829079 0.91 MAOB (0.41) MAOBMMP1MMP2MMP9EGFR
SCHEMBL1060129 0.91 MAOB (0.41) MAOBMMP1MMP2MMP9EGFR
SCHEMBL4830990 0.91 MAOB (0.41) MAOBMMP1MMP2MMP9EGFR
SCHEMBL4833879 0.85 MAOB (0.43) MAOBMMP1MMP2MMP9EGFR
SCHEMBL4833906 0.85 MAOB (0.43) MAOBMMP1MMP2MMP9EGFR
SCHEMBL4829260 0.84 FLT1 (0.42) MAOBMCHR1LMNANPC1RAB9A
SCHEMBL4829241 0.84 FLT1 (0.42) MAOBMCHR1LMNANPC1RAB9A
SCHEMBL4829186 0.83 HDAC1 (0.39) MMP1MMP2MMP9EGFRCCNC
SCHEMBL4829207 0.83 HDAC1 (0.39) MMP1MMP2MMP9EGFRCCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 MAOB 881/4885MMP1 4721/4885MMP2 4741/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 MAOB 881/4885MMP1 4721/4885MMP2 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.